32 results
8-K
ALPN
Alpine Immune Sciences Inc
21 Dec 23
Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie
4:23pm
to provide AbbVie with a data package based on the Analysis and including certain information described in the Amendment (the “Revised Data Package … ”). AbbVie may exercise the Option until its expiration 90 days following the date the Company delivers to AbbVie the Revised Data Package, subject
8-K
EX-99.1
ALPN
Alpine Immune Sciences Inc
21 Dec 23
Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie
4:23pm
is exercisable by AbbVie at any time and will expire 90 days from delivery of an agreed upon data package by the Company to AbbVie.
The previously disclosed
424B5
vg8q755kr utxg0ce4y
7 Nov 23
Prospectus supplement for primary offering
8:15pm
424B5
y19pr9v8m798mc
6 Nov 23
Prospectus supplement for primary offering
6:05am
424B5
d8crcjhh60zq1 xdctuf
11 May 23
Prospectus supplement for primary offering
4:43pm
424B5
noy0heo4
21 Sep 22
Prospectus supplement for primary offering
5:18pm
424B5
0z0o9ehhm
20 Sep 22
Prospectus supplement for primary offering
4:20pm